Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2024

15-07-2023 | Metastasis | Review

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance

Authors: Zhenli Guo, Milad Ashrafizadeh, Wei Zhang, Rongjun Zou, Gautam Sethi, Xianbin Zhang

Published in: Cancer and Metastasis Reviews | Issue 1/2024

Login to get access

Abstract

The metastasis is a multistep process in which a small proportion of cancer cells are detached from the colony to enter into blood cells for obtaining a new place for metastasis and proliferation. The metastasis and cell plasticity are considered major causes of cancer-related deaths since they improve the malignancy of cancer cells and provide poor prognosis for patients. Furthermore, enhancement in the aggressiveness of cancer cells has been related to the development of drug resistance. Metastasis of pancreatic cancer (PC) cells has been considered one of the major causes of death in patients and their undesirable prognosis. PC is among the most malignant tumors of the gastrointestinal tract and in addition to lifestyle, smoking, and other factors, genomic changes play a key role in its progression. The stimulation of EMT in PC cells occurs as a result of changes in molecular interaction, and in addition to increasing metastasis, EMT participates in the development of chemoresistance. The epithelial, mesenchymal, and acinar cell plasticity can occur and determines the progression of PC. The major molecular pathways including STAT3, PTEN, PI3K/Akt, and Wnt participate in regulating the metastasis of PC cells. The communication in tumor microenvironment can provide by exosomes in determining PC metastasis. The components of tumor microenvironment including macrophages, neutrophils, and cancer-associated fibroblasts can modulate PC progression and the response of cancer cells to chemotherapy.

Graphical Abstract

Literature
1.
Zeng, S., et al. (2019). Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences, 20(18), 4504.PubMedPubMedCentral
2.
Rahib, L., et al. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74(11), 2913–2921.PubMed
3.
Kamisawa, T., et al. (2016). Pancreatic cancer. Lancet, 388(10039), 73–85.PubMed
4.
Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World journal of oncology, 10(1), 10–27.PubMedPubMedCentral
5.
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a Cancer Journal for Clinicians, 68(1), 7–30.PubMed
6.
Kleeff, J., et al. (2016). Pancreatic cancer. Nature reviews Disease primers, 2, 16022.PubMed
7.
Kaur, S., et al. (2017). A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer: A multicenter study. The American Journal of Gastroenterology, 112(1), 172–183.PubMed
8.
Kaur, S., et al. (2012). Early diagnosis of pancreatic cancer: challenges and new developments. Biomarkers in Medicine, 6(5), 597–612.PubMed
9.
Papaefthymiou, A., Doukatas, A., & Galanopoulos, M. (2022). Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance. Clinics and Research in Hepatology and Gastroenterology, 46(5), 101911.PubMed
10.
Kamimura, K., Yokoo, T., & Terai, S. (2018). Gene therapy for pancreatic diseases: current status. International journal of molecular sciences, 19(11), 3415.PubMedPubMedCentral
11.
Hu, C., et al. (2018). Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. Jama, 319(23), 2401–2409.PubMedPubMedCentral
12.
Di Magliano, M. P., & Logsdon, C. D. J. G. (2013). Roles for KRAS in pancreatic tumor development and progression. Gastroenterology, 144(6), 1220–1229.PubMed
13.
Gleeson, F. C., et al. (2016). Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Oncotarget, 7(34), 54526.PubMedPubMedCentral
14.
Wang, S., et al. (2020). Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. American Journal of Cancer Research, 10(7), 1937–1953.PubMedPubMedCentral
15.
Jones, S., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321(5897), 1801–1806.PubMedPubMedCentral
16.
Zhang, D., et al. (2022). SEMA3C supports pancreatic cancer progression by regulating the autophagy process and tumor immune microenvironment. Frontiers in Oncology, 12, 890154.PubMedPubMedCentral
17.
Li, M., et al. (2022). IPO7 promotes pancreatic cancer progression via regulating ERBB pathway. Clinics (São Paulo, Brazil), 77, 100044.PubMed
18.
Cao, J. Z., et al. (2022). UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation. Journal of gastrointestinal oncology, 13(3), 1444–1453.PubMedPubMedCentral
19.
Wen, Z., et al. (2022). COL10A1-DDR2 axis promotes the progression of pancreatic cancer by regulating MEK/ERK signal transduction. Frontiers in Oncology, 12, 1049345.PubMedPubMedCentral
20.
Li, J., et al. (2022). HOXA10 promote pancreatic cancer progression via directly activating canonical NF-κB signaling pathway. Carcinogenesis, 43(8), 787–796.PubMed
21.
Song, Y., Gao, Z., & Zheng, C. (2022). Silencing LINC01234 represses pancreatic cancer progression by inhibiting the malignant phenotypes of pancreatic cancer cells. Immunobiology, 227(6), 152295.PubMed
22.
Shi, J., et al. (2022). JNK inhibitor IX restrains pancreatic cancer through p53 and p21. Frontiers in Oncology, 12, 1006131.PubMedPubMedCentral
23.
Nimmakayala, R. K., et al. (2022). PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Cell Death & Disease, 13(10), 839.
24.
Park, S. J., et al. (2023). Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer. Cancer Research, 83(5), 735–752.PubMed
25.
Liu, H., et al. (2023). Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Cancer Letters, 555, 216040.PubMed
26.
Huang, C. K., et al. (2023). ENO1 promotes immunosuppression and tumor growth in pancreatic cancer. Clinical & Translational Oncology, 25(7), 2250–2264.
27.
Wu, J. (2022). Pancreatic cancer-derived exosomes promote the proliferation, invasion, and metastasis of pancreatic cancer by the miR-3960/TFAP2A Axis. Journal of Oncology, 2022, 3590326.PubMedPubMedCentral
28.
Zhang, W., et al. (2022). Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Cell Death & Disease, 13(7), 630.
29.
Jacoberger-Foissac, C., et al. (2023). CD73 Inhibits cGAS-STING and cooperates with CD39 to promote pancreatic cancer. Cancer Immunology Research, 11(1), 56–71.PubMedPubMedCentral
30.
Simmler, P., et al. (2022). SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. Cell Reports, 40(8), 111266.PubMed
31.
Lee, M. S., et al. (2023). Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature, 616(7956), 339–347.PubMedPubMedCentral
32.
Lefler, J. E., et al. (2022). STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Life Science Alliance, 5(11), 1.
33.
Su, H., et al. (2022). Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Nature, 610(7931), 366–372.PubMedPubMedCentral
34.
Rademaker, G., et al. (2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biology, 53, 102324.PubMedPubMedCentral
35.
Lan, L., et al. (2022). GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature, 607(7917), 163–168.PubMed
36.
Wang, S., et al. (2022). RNA-binding proteins and cancer metastasis. In Seminars in Cancer Biology. Elsevier.
37.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: The'seed and soil'hypothesis revisited. Nature reviews cancer, 3(6), 453–458.PubMed
38.
Chambers, A. F., Groom, A. C., & MacDonald, I. C. J. N. R. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563–572.PubMed
39.
Polyak, K., & Weinberg, R. A. J. N. R. C. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265–273.PubMed
40.
41.
Yang, Y., & Cao, Y. (2022). The impact of VEGF on cancer metastasis and systemic disease. In Seminars in Cancer Biology. Elsevier.
42.
Friedl, P., & Alexander, S. J. C. (2011). Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell, 147(5), 992–1009.PubMed
43.
Sun, X., et al. (2022). Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut, 71(1), 129–147.PubMed
44.
Yang, Y., et al. (2016). The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nature communications, 7(1), 11385.PubMedPubMedCentral
45.
Li, Y., et al. (2022). METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions. Nature Communications, 13(1), 6350.PubMedPubMedCentral
46.
Delaunay, S., et al. (2022). Mitochondrial RNA modifications shape metabolic plasticity in metastasis. Nature, 607(7919), 593–603.PubMedPubMedCentral
47.
Du, Q., et al. (2022). FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis. Cell Death & Disease, 13(5), 488.
48.
Liu, W., et al. (2022). MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3. Oncogene, 41(41), 4606–4617.PubMed
49.
Meng, Q., et al. (2022). Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis. Oncogene, 41(32), 3912–3924.PubMed
50.
Li, F., et al. (2022). Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis. Signal Transduction and Targeted Therapy, 7(1), 264.PubMedPubMedCentral
51.
Verma, A., et al. (2022). EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nature Communications, 13(1), 7344.PubMedPubMedCentral
52.
Mirzaei, S., et al. (2023). Exosome-mediated miR-200a delivery into TGF-β-treated AGS cells abolished epithelial-mesenchymal transition with normalization of ZEB1, vimentin and Snail1 expression. Environmental Research, 231(Part 1), 116115.
53.
Ashrafizadeh, M., et al. (2020). Association of the epithelial–mesenchymal transition (EMT) with cisplatin resistance. International journal of molecular sciences, 21(11), 4002.PubMedPubMedCentral
54.
Ashrafizadeh, M., et al. (2021). New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomedicine & Pharmacotherapy, 141, 111824.
55.
Recouvreux, M. V., et al. (2020). Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. The Journal of Experimental Medicine, 217(9), 1.
56.
Sheng, W., et al. (2020). Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. Journal of Experimental & Clinical Cancer Research, 39(1), 16.
57.
Sheng, W., et al. (2017). Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. Cell Death & Disease, 8(10), e3147.
58.
Chen, Y., et al. (2020). FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling. Biology open, 9(2), bio048462.PubMedPubMedCentral
59.
Fu, X., et al. (2021). Downregulation of NEAT1 sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine through modulation of the miR-506-3p/ZEB2/EMT axis. American Journal of Cancer Research, 11(8), 3841–3856.PubMedPubMedCentral
60.
Simeonov, K. P., et al. (2021). Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell, 39(8), 1150–1162.e9.PubMedPubMedCentral
61.
Zhang, X., et al. (2022). MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1. Cell Death & Disease, 13(11), 923.
62.
Li, N., et al. (2018). Emodin inhibits pancreatic cancer EMT and invasion by up-regulating microRNA-1271. Molecular Medicine Reports, 18(3), 3366–3374.PubMedPubMedCentral
63.
Sun, L., et al. (2019). Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. International Journal of Oncology, 54(1), 98–110.PubMed
64.
Liu, F., et al. (2019). SMARCAD1 promotes pancreatic cancer cell growth and metastasis through Wnt/β-catenin-mediated EMT. International Journal of Biological Sciences, 15(3), 636–646.PubMedPubMedCentral
65.
Peng, X., et al. (2022). Calpain2 upregulation regulates EMT-mediated pancreatic cancer metastasis via the Wnt/β-catenin Signaling Pathway. Frontiers of medicine (Lausanne), 9, 783592.
66.
Tan, J., et al. (2014). Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicology Letters, 224(1), 7–15.PubMed
67.
Yang, R. M., et al. (2017). miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Cell Death & Disease, 8(10), e3129.
68.
Li, Y., et al. (2019). Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT. Cancer Letters, 459, 15–29.PubMed
69.
Okada, Y., et al. (2021). LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis, 42(4), 546–556.PubMedPubMedCentral
70.
An, N., & Zheng, B. (2020). MiR-203a-3p inhibits pancreatic cancer cell proliferation, EMT, and apoptosis by regulating SLUG. Technology in Cancer Research & Treatment, 19, 1533033819898729.
71.
72.
Yu, S., et al. (2021). Circ_0092367 Inhibits EMT and gemcitabine resistance in pancreatic cancer via regulating the miR-1206/ESRP1 axis. Genes (Basel), 12(11), 1701.PubMed
73.
Zhao, Y., et al. (2021). Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling. Cancer Cell International, 21(1), 670.PubMedPubMedCentral
74.
Hu, W., et al. (2019). IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT) through Wnt/β-catenin signaling. Scientific Reports, 9(1), 7539.PubMedPubMedCentral
75.
Wang, W., et al. (2018). E-cadherin is downregulated by microenvironmental changes in pancreatic cancer and induces EMT. Oncology Reports, 40(3), 1641–1649.PubMed
76.
Garg, R., et al. (2022). Targeting FTO suppresses pancreatic carcinogenesis via regulating stem cell maintenance and EMT pathway. Cancers (Basel), 14(23), 5919.PubMed
77.
Santoro, R., et al. (2018). MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. Anticancer Research, 38(4), 1937–1946.PubMed
78.
Li, W., et al. (2020). Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor-stromal crosstalk under hypoxic conditions via the IL-6/ERK/NF-κB axis. Oncology Reports, 44(1), 382–392.PubMed
79.
Sheng, W., et al. (2020). Calreticulin promotes EMT in pancreatic cancer via mediating Ca(2+) dependent acute and chronic endoplasmic reticulum stress. Journal of Experimental & Clinical Cancer Research, 39(1), 209.
80.
Yan, T., et al. (2017). Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization. Oncology Letters, 14(5), 5400–5408.PubMedPubMedCentral
81.
Weadick, B., et al. (2021). EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1. Molecular Cancer Therapeutics, 20(2), 410–422.PubMed
82.
Zhu, S., et al. (2017). ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca(2+)/RhoA pathway. Cell Death & Disease, 8(5), e2806.
83.
Shi, C., et al. (2021). NUDCD1 knockdown inhibits the proliferation, migration, and invasion of pancreatic cancer via the EMT process. Aging (Albany NY), 13(14), 18298–18309.PubMed
84.
Zhang, Z., et al. (2017). miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomedicine & Pharmacotherapy, 96, 1341–1348.
85.
Rumman, M., et al. (2016). HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Oncotarget, 7(47), 78029–78047.PubMedPubMedCentral
86.
Shen, J., et al. (2019). LncRNA XIST promotes pancreatic cancer migration, invasion and EMT by sponging miR-429 to modulate ZEB1 expression. The International Journal of Biochemistry & Cell Biology, 113, 17–26.
87.
Zhang, R., et al. (2021). Silencing of circRNA circ_0001666 represses EMT in pancreatic cancer through upregulating miR-1251 and downregulating SOX4. Frontiers in Molecular Biosciences, 8, 684866.PubMedPubMedCentral
88.
Zhang, Y., et al. (2019). Upregulation of LASP2 inhibits pancreatic cancer cell migration and invasion through suppressing TGF-β-induced EMT. Journal of Cellular Biochemistry, 120(8), 13651–13657.PubMed
89.
Bhutia, Y. D., et al. (2020). Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer. Asian Journal of Pharmaceutical Sciences, 15(2), 237–251.PubMedPubMedCentral
90.
Li, P., et al. (2020). FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Aging (Albany NY), 12(1), 53–69.PubMed
91.
Zhang, L., et al. (2016). CCL21/CCR7 axis contributed to CD133+ pancreatic cancer stem-like cell metastasis via EMT and Erk/NF-κB pathway. PLoS One, 11(8), e0158529.PubMedPubMedCentral
92.
Zhao, H., et al. (2017). Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. Journal of Cellular and Molecular Medicine, 21(9), 2055–2067.PubMedPubMedCentral
93.
Martinelli, P., et al. (2017). GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 66(9), 1665–1676.PubMed
94.
Gao, C., et al. (2021). Yap1-2 Isoform Is the Primary Mediator in TGF-β1 Induced EMT in Pancreatic Cancer. Frontiers in Oncology, 11, 649290.PubMedPubMedCentral
95.
Baer, R., et al. (2014). Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α. Genes & Development, 28(23), 2621–2635.
96.
Sancho, P., et al. (2015). MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism, 22(4), 590–605.PubMed
97.
Zhao, S., et al. (2016). CD44 expression level and isoform contributes to pancreatic cancer cell plasticity, invasiveness, and response to therapy. Clinical Cancer Research, 22(22), 5592–5604.PubMedPubMedCentral
98.
Suzuki, K., et al. (2017). Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. Oncotarget, 8(39), 66098–66111.PubMedPubMedCentral
99.
Cruz, V. H., et al. (2019). Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. JCI Insight, 5(9), e126117.PubMed
100.
Kirane, A., et al. (2015). Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research, 75(18), 3699–3705.PubMedPubMedCentral
101.
Feldmann, K., et al. (2021). Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology, 160(1), 346–361.e24.PubMed
102.
Perusina Lanfranca, M., et al. (2020). Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice. Gastroenterology, 158(5), 1417–1432.e11.PubMed
103.
Sharma, N., et al. (2020). Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer and Metabolism, 8, 19.PubMedPubMedCentral
104.
Yi, Z., et al. (2022). KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway. Cellular and Molecular Gastroenterology and Hepatology, 13(2), 643–667.PubMed
105.
Singh, S. K., et al. (2015). Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. The EMBO Journal, 34(4), 517–530.PubMedPubMedCentral
106.
Liu, M., et al. (2021). Zinc-Dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer. Gastroenterology, 160(5), 1771–1783.e1.PubMed
107.
Krebs, A. M., et al. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology, 19(5), 518–529.PubMed
108.
Kloesch, B., et al. (2022). A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Gut, 71(4), 766–777.PubMed
109.
Nishino, H., et al. (2017). Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Cancer Medicine, 6(11), 2686–2696.PubMedPubMedCentral
110.
Raghavan, S., et al. (2021). Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell, 184(25), 6119–6137.e26.PubMedPubMedCentral
111.
Ireland, L., et al. (2020). Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis. Frontiers in Immunology, 11, 297.PubMedPubMedCentral
112.
Datta, J., et al. (2022). Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer. Gastroenterology, 163(6), 1593–1612.PubMed
113.
Cao, R., et al. (2020). miR-3613-5p enhances the metastasis of pancreatic cancer by targeting CDK6. Cell Cycle, 19(22), 3086–3095.PubMedPubMedCentral
114.
Chen, Z., et al. (2018). MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. Molecular and Cellular Probes, 40, 19–26.PubMed
115.
Wu, X., et al. (2018). MiR-216b inhibits pancreatic cancer cell progression and promotes apoptosis by down-regulating KRAS. Archives of Medical Science, 14(6), 1321–1332.PubMed
116.
Zhang, D., et al. (2021). MiR-489-3p reduced pancreatic cancer proliferation and metastasis by targeting PKM2 and LDHA involving glycolysis. Frontiers in Oncology, 11, 651535.PubMedPubMedCentral
117.
118.
Mirzaei, S., et al. (2022). Molecular landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention. Journal of Experimental & Clinical Cancer Research, 41(1), 214.
119.
Luo, Y., et al. (2020). LncRNA DANCR promotes proliferation and metastasis in pancreatic cancer by regulating miRNA-33b. FEBS Open Bio, 10(1), 18–27.PubMed
120.
Hui, B., et al. (2019). RREB1-induced upregulation of the lncRNA AGAP2-AS1 regulates the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4. Cell Death & Disease, 10(3), 207.
121.
Feng, Y., et al. (2020). LncRNA NEAT1 facilitates pancreatic cancer growth and metastasis through stabilizing ELF3 mRNA. American Journal of Cancer Research, 10(1), 237–248.PubMedPubMedCentral
122.
Ren, X., et al. (2020). lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Molecular Cancer, 19(1), 35.PubMedPubMedCentral
123.
Shen, X., et al. (2021). Identification of Circ_001569 as a Potential biomarker in the diagnosis and prognosis of pancreatic cancer. Technology in Cancer Research & Treatment, 20, 1533033820983302.
124.
Zhang, J., et al. (2023). Circ_0000284 upregulates RHPN2 to facilitate pancreatic cancer proliferation, metastasis, and angiogenesis through sponging miR-1179. Journal of Biochemical and Molecular Toxicology, 37(3), e23274.PubMed
125.
Li, C., et al. (2023). Downregulation of circ-STK39 suppresses pancreatic cancer progression by sponging mir-140-3p and regulating TRAM2-mediated epithelial-mesenchymal transition. Apoptosis, 28, 1024–1034.PubMed
126.
Li, M., et al. (2020). miR-193a-5p promotes pancreatic cancer cell metastasis through SRSF6-mediated alternative splicing of OGDHL and ECM1. American Journal of Cancer Research, 10(1), 38–59.PubMedPubMedCentral
127.
Mody, H. R., et al. (2017). miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer. Molecular Cancer Research, 15(8), 1029–1039.PubMed
128.
Jiang, J., et al. (2015). Reduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype. Oncotarget, 6(5), 2767–2778.PubMed
129.
Wu, X., et al. (2016). MiR-200a suppresses the proliferation and metastasis in pancreatic ductal adenocarcinoma through downregulation of DEK Gene. Translational Oncology, 9(1), 25–31.PubMedPubMedCentral
130.
Hu, Y., et al. (2012). miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biology, 33(6), 1863–1870.PubMed
131.
Chen, Y., et al. (2019). MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer. International Journal of Oncology, 55(1), 142–156.PubMedPubMedCentral
132.
Ma, L., et al. (2019). The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer. Cancer Cell International, 19, 248.PubMedPubMedCentral
133.
Wang, L., Mu, N., & Qu, N. (2021). Methylation of the miR-29b-3p promoter contributes to angiogenesis, invasion, and migration in pancreatic cancer. Oncology Reports, 45(1), 65–72.PubMedPubMedCentral
134.
Ma, C., et al. (2014). miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. Journal of Experimental & Clinical Cancer Research, 33(1), 54.
135.
Xue, L., et al. (2020). miR-539 suppresses the proliferation, migration, invasion and epithelial mesenchymal transition of pancreatic cancer cells through targeting SP1. International Journal of Molecular Medicine, 45(6), 1771–1782.PubMedPubMedCentral
136.
Hiramoto, H., et al. (2017). miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Scientific Reports, 7(1), 4002.PubMedPubMedCentral
137.
Deng, S. J., et al. (2018). Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene, 37(44), 5811–5828.PubMed
138.
Cheng, C., et al. (2022). Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Cancer Science, 113(9), 2986–3001.PubMedPubMedCentral
139.
Lou, S., et al. (2019). Downregulation of lncRNA AFAP1-AS1 by oridonin inhibits the epithelial-to-mesenchymal transition and proliferation of pancreatic cancer cells. Acta Biochimica et Biophysica Sinica Shanghai, 51(8), 814–825.
140.
Cui, X. P., et al. (2019). LncRNA TP73-AS1 sponges miR-141-3p to promote the migration and invasion of pancreatic cancer cells through the up-regulation of BDH2. Bioscience Reports, 39(3), BSR20181937.PubMedPubMedCentral
141.
Liu, W., et al. (2020). A novel lncRNA PTTG3P/miR-132/212-3p/FoxM1 feedback loop facilitates tumorigenesis and metastasis of pancreatic cancer. Cell death discovery, 6(1), 136.PubMedPubMedCentral
142.
An, Y., et al. (2018). LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer. Cancer Cell International, 18, 143.PubMedPubMedCentral
143.
Liu, B., et al. (2018). lncRNA GAS5 reverses EMT and tumor stem cell-mediated gemcitabine resistance and metastasis by targeting miR-221/SOCS3 in pancreatic cancer. Molecular Therapy--Nucleic Acids, 13, 472–482.PubMedPubMedCentral
144.
Gu, L., et al. (2017). lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. Biomedicine & Pharmacotherapy, 89, 1269–1276.
145.
Liu, S., et al. (2019). LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p. Biomedicine & Pharmacotherapy, 114, 108862.
146.
Deng, P. C., et al. (2019). LncRNA SNHG14 potentiates pancreatic cancer progression via modulation of annexin A2 expression by acting as a competing endogenous RNA for miR-613. Journal of Cellular and Molecular Medicine, 23(11), 7222–7232.PubMedPubMedCentral
147.
Huang, S., et al. (2021). LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 25(9), 4275–4286.PubMedPubMedCentral
148.
Chen, S., et al. (2020). LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression. Clinical Epigenetics, 12(1), 168.PubMedPubMedCentral
149.
Cai, J., et al. (2021). Curcumin attenuates lncRNA H19-induced epithelial-mesenchymal transition in tamoxifen-resistant breast cancer cells. Molecular Medicine Reports, 23(1), 1.
150.
Zhou, M., et al. (2022). LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Journal of Experimental & Clinical Cancer Research, 41(1), 288.
151.
Cai, H., et al. (2017). LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer. Oncotarget, 8(20), 32905–32917.PubMedPubMedCentral
152.
Miao, H., et al. (2021). LncRNA TP73-AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA -200a sponging. Journal of Cellular and Molecular Medicine, 25(7), 3654–3664.PubMedPubMedCentral
153.
Zhang, X., et al. (2020). Circ_0075829 facilitates the progression of pancreatic carcinoma by sponging miR-1287-5p and activating LAMTOR3 signalling. Journal of Cellular and Molecular Medicine, 24(24), 14596–14607.PubMedPubMedCentral
154.
Xing, C., et al. (2019). Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression. Artificial Cells, Nanomedicine and Biotechnology, 47(1), 3920–3928.PubMed
155.
Wang, K. Q., et al. (2022). Circular RNA fibroblast growth factor receptor 1 promotes pancreatic cancer progression by targeting microRNA-532-3p/PIK3CB Axis. Pancreas, 51(8), 930–942.PubMed
156.
Messex, J. K., et al. (2022). Oncogenic Kras-mediated cytokine CCL15 regulates pancreatic cancer cell migration and invasion through ROS. Cancers (Basel), 14(9), 2153.PubMed
157.
Deng, J., et al. (2022). High Glucose promotes pancreatic ductal adenocarcinoma gemcitabine resistance and invasion through modulating ROS/MMP-3 signaling pathway. Oxidative Medicine and Cellular Longevity, 2022, 3243647.PubMedPubMedCentral
158.
Binker-Cosen, M. J., et al. (2017). Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-κB/MMP-9 signaling pathway. Biochemical and Biophysical Research Communications, 484(1), 152–158.PubMed
159.
Shimojo, Y., et al. (2013). Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clinical & Experimental Metastasis, 30(2), 143–154.
160.
Wörmann, S. M., et al. (2021). APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nature Cancer, 2(12), 1338–1356.PubMed
161.
Zhao, T., et al. (2020). IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Theranostics, 10(9), 4088–4100.PubMedPubMedCentral
162.
Hu, H., et al. (2020). MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. Carcinogenesis, 41(4), 502–514.PubMed
163.
Huang, C., et al. (2011). STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. International Journal of Oncology, 38(6), 1637–1644.PubMed
164.
Fofaria, N. M., & Srivastava, S. K. (2015). STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis, 36(1), 142–150.PubMed
165.
Chen, H., et al. (2023). Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. Clinical Cancer Research, 29(4), 815–830.PubMed
166.
Li, H., et al. (2011). STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One, 6(10), e25941.PubMedPubMedCentral
167.
Li, Y., Zhang, Y., & Liu, J. (2019). NETO2 promotes pancreatic cancer cell proliferation, invasion and migration via activation of the STAT3 signaling pathway. Cancer Management and Research, 11, 5147–5156.PubMedPubMedCentral
168.
Hu, B., et al. (2016). HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. Cancer Letters, 376(2), 387–398.PubMed
169.
Zuo, C., et al. (2018). Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. Pancreatology, 18(3), 328–333.PubMed
170.
Lian, J., et al. (2020). Ubiquitin specific peptidase 5 enhances STAT3 signaling and promotes migration and invasion in Pancreatic Cancer. Journal of Cancer, 11(23), 6802–6811.PubMedPubMedCentral
171.
Chen, J., et al. (2016). Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Oncotargets and Therapy, 9, 4225–4237.PubMedPubMedCentral
172.
Zhang, Z., et al. (2019). BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Cancer Letters, 449, 215–225.PubMed
173.
174.
Liu, L., et al. (2019). Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway. Hepatobiliary & Pancreatic Diseases International, 18(6), 580–586.
175.
Guo, Y., et al. (2021). The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Aging (Albany NY), 13(14), 18545–18563.PubMed
176.
Al-Ismaeel, Q., et al. (2019). ZEB1 and IL-6/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 proteins. British Journal of Cancer, 121(1), 65–75.PubMedPubMedCentral
177.
Su, K., et al. (2023). Solasodine suppresses the metastasis of gastric cancer through claudin-2 via the AMPK/STAT3/NF-κB pathway. Chemico-Biological Interactions, 379, 110520.PubMed
178.
Huang, C., et al. (2013). Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. Oncology Reports, 30(3), 1223–1230.PubMed
179.
Zhao, G., et al. (2013). MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS One, 8(9), e73803.PubMedPubMedCentral
180.
Wei, D., et al. (2003). Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 22(3), 319–329.PubMed
181.
Zhao, S., et al. (2008). Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Research, 68(11), 4221–4228.PubMed
182.
Sasaki, N., et al. (2022). Gp130-Mediated STAT3 Activation contributes to the aggressiveness of pancreatic cancer through H19 long non-coding RNA expression. Cancers (Basel), 14(9), 2055.PubMed
183.
Wu, Y. S., et al. (2017). Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells. Biochimica et Biophysica Acta - General Subjects, 1861(2), 296–306.PubMed
184.
Liu, M., et al. (2019). Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Theranostics, 9(16), 4795–4810.PubMedPubMedCentral
185.
Jin, Y., et al. (2021). Positive Reciprocal Feedback of lncRNA ZEB1-AS1 and HIF-1α contributes to hypoxia-promoted tumorigenesis and metastasis of pancreatic cancer. Frontiers in Oncology, 11, 761979.PubMedPubMedCentral
186.
Niu, Y., et al. (2018). MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Oncogene, 37(13), 1743–1758.PubMed
187.
Yue, H., Liu, L., & Song, Z. (2019). miR-212 regulated by HIF-1α promotes the progression of pancreatic cancer. Experimental and Therapeutic Medicine, 17(3), 2359–2365.PubMedPubMedCentral
188.
Wang, L., et al. (2021). N2E4, a Monoclonal antibody targeting neuropilin-2, inhibits tumor growth and metastasis in pancreatic ductal adenocarcinoma via suppressing FAK/Erk/HIF-1α Signaling. Frontiers in Oncology, 11, 657008.PubMedPubMedCentral
189.
Zhang, D., et al. (2016). β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Oncotarget, 7(14), 17760–17772.PubMed
190.
Zeng, Z., et al. (2019). LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Theranostics, 9(18), 5298–5314.PubMedPubMedCentral
191.
Zhu, G. H., et al. (2013). Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. Digestive Diseases and Sciences, 58(12), 3503–3515.PubMed
192.
Zhang, Q., et al. (2020). Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Investigational New Drugs, 38(2), 321–328.PubMed
193.
Gao, Z. Q., et al. (2017). Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell & Bioscience, 7, 66.
194.
Liu, Y., et al. (2020). Role of miR-92a-3p/PTEN axis in regulation of pancreatic cancer cell proliferation and metastasis. Zhong Nan Da Xue Xue Bao. Yi Xue Ban, 45(3), 280–289.PubMed
195.
Gu, J., et al. (2016). GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Letters, 380(2), 434–441.PubMed
196.
Wang, M. C., et al. (2016). Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study. Oncotarget, 7(8), 9586–9599.PubMedPubMedCentral
197.
Zhao, H., et al. (2014). Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes, Obesity and Metabolism, 16(9), 850–860.PubMed
198.
Fujita, M., et al. (2014). Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation. FEBS Letters, 588(17), 3240–3250.PubMed
199.
Li, H., et al. (2014). Effect of PTEN and KAI1 gene overexpression on the proliferation, metastasis and radiosensitivity of ASPC-1 pancreatic cancer cells under hypoxic conditions. Molecular Medicine Reports, 10(4), 1973–1977.PubMed
200.
Ma, J., et al. (2010). IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. The Journal of Surgical Research, 160(1), 90–101.PubMed
201.
Zhang, H., et al. (2019). MiR-132 promotes the proliferation, invasion and migration of human pancreatic carcinoma by inhibition of the tumor suppressor gene PTEN. Progress in Biophysics and Molecular Biology, 148, 65–72.PubMed
202.
Zhang, H., et al. (2019). Long non-coding RNA CASC2 upregulates PTEN to suppress pancreatic carcinoma cell metastasis by downregulating miR-21. Cancer Cell International, 19, 18.PubMedPubMedCentral
203.
Wu, Y., et al. (2019). ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. Experimental Cell Research, 379(1), 30–47.PubMed
204.
Zhu, J. H., et al. (2020). MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1866(6), 165747.PubMed
205.
Li, W., et al. (2018). Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. International Journal of Oncology, 52(5), 1593–1602.PubMed
206.
Liu, X., et al. (2018). Phosphoglycerate Mutase 1 (PGAM1) Promotes pancreatic ductal adenocarcinoma (PDAC) Metastasis by acting as a novel downstream target of the PI3K/Akt/mTOR Pathway. Oncology Research, 26(7), 1123–1131.PubMedPubMedCentral
207.
Deng, J., et al. (2021). N(6) -methyladenosine-mediated upregulation of WTAPP1 promotes WTAP translation and Wnt signaling to facilitate pancreatic cancer progression. Cancer Research, 81(20), 5268–5283.PubMedPubMedCentral
208.
Gokturk, F., Erkoc-Kaya, D., & Arikoglu, H. (2021). Juglone can inhibit angiogenesis and metastasis in pancreatic cancer cells by targeting Wnt/β-catenin signaling. Bratislavské Lekárske Listy, 122(2), 132–137.PubMed
209.
Chen, T., et al. (2020). Linc00261 inhibits metastasis and the WNT signaling pathway of pancreatic cancer by regulating a miR-552-5p/FOXO3 axis. Oncology Reports, 43(3), 930–942.PubMedPubMedCentral
210.
Xu, D., et al. (2020). Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling. Journal of Cancer, 11(8), 2101–2112.PubMedPubMedCentral
211.
Nielsen, M. F., Mortensen, M. B., & Detlefsen, S. (2016). Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World Journal of Gastroenterology, 22(9), 2678–2700.PubMedPubMedCentral
212.
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020). Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nature Reviews. Gastroenterology & Hepatology, 17(8), 487–505.
213.
Veenstra, V. L., et al. (2018). ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 7(11), 87.PubMedPubMedCentral
214.
Cannon, A., et al. (2018). Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes & Cancer, 9(3-4), 78–86.
215.
Schnittert, J., et al. (2019). Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. The FASEB Journal, 33(5), 6609–6621.PubMed
216.
Goehrig, D., et al. (2019). Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut, 68(4), 693–707.PubMed
217.
Awaji, M., & Singh, R. K. (2019). Cancer-associated fibroblasts' functional heterogeneity in pancreatic ductal adenocarcinoma. Cancers (Basel), 11(3), 290.PubMed
218.
Sun, Q., et al. (2018). The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics, 8(18), 5072–5087.PubMedPubMedCentral
219.
Kobayashi, H., et al. (2019). Cancer-associated fibroblasts in gastrointestinal cancer. Nature Reviews. Gastroenterology & Hepatology, 16(5), 282–295.
220.
Geleta, B., et al. (2022). Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. The Journal of Biological Chemistry, 298(3), 101608.PubMedPubMedCentral
221.
Liu, Q. Q., et al. (2016). Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway. Cancer Cell International, 16, 57.PubMedPubMedCentral
222.
Quan, M., et al. (2015). Merlin/NF2 suppresses pancreatic tumor growth and metastasis by attenuating the FOXM1-mediated Wnt/β-Catenin signaling. Cancer Research, 75(22), 4778–4789.PubMedPubMedCentral
223.
Li, F., Dai, L., & Niu, J. (2020). GPX2 silencing relieves epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer by downregulating Wnt pathway. Journal of Cellular Physiology, 235(11), 7780–7790.PubMed
224.
Garg, B., et al. (2017). Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. Cancer Letters, 388, 64–72.PubMed
225.
Jiang, H., et al. (2014). Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer. American Journal of Cancer Research, 4(5), 537–544.PubMedPubMedCentral
226.
Zhou, P., et al. (2019). NMIIA promotes tumor growth and metastasis by activating the Wnt/β-catenin signaling pathway and EMT in pancreatic cancer. Oncogene, 38(27), 5500–5515.PubMed
227.
Wang, L., et al. (2009). Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell, 15(3), 207–219.PubMedPubMedCentral
228.
Sun, Y., et al. (2019). Restoration of miRNA-148a in pancreatic cancer reduces invasion and metastasis by inhibiting the Wnt/β-catenin signaling pathway via downregulating maternally expressed gene-3. Experimental and Therapeutic Medicine, 17(1), 639–648.PubMed
229.
Zhang, Q., et al. (2017). Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Molecular Cancer, 16(1), 119.PubMedPubMedCentral
230.
Weng, Y. C., et al. (2019). Long non-coding RNA LINC01133 silencing exerts antioncogenic effect in pancreatic cancer through the methylation of DKK1 promoter and the activation of Wnt signaling pathway. Cancer Biology & Therapy, 20(3), 368–380.
231.
Wu, X., et al. (2019). LncRNA BANCR promotes pancreatic cancer tumorigenesis via modulating MiR-195-5p/Wnt/β-catenin signaling pathway. Technology in Cancer Research & Treatment, 18, 1533033819887962.
232.
Yang, Y., Bai, Y. S., & Wang, Q. (2017). CDGSH iron sulfur domain 2 activates proliferation and EMT of pancreatic cancer cells via Wnt/β-catenin pathway and has prognostic value in human pancreatic cancer. Oncology Research, 25(4), 605–615.PubMedPubMedCentral
233.
Kim, J. H., et al. (2022). Vitamin C suppresses pancreatic carcinogenesis through the inhibition of both glucose metabolism and Wnt signaling. International Journal of Molecular Sciences, 23(20), 12249.PubMedPubMedCentral
234.
Zhan, T., et al. (2020). miR-455-3p functions as a tumor suppressor by restraining Wnt/β-catenin signaling via TAZ in pancreatic cancer. Cancer Management and Research, 12, 1483–1492.PubMedPubMedCentral
235.
Yang, J., et al. (2019). Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer. Cancer Management and Research, 11, 4209–4221.PubMedPubMedCentral
236.
Wang, Z., et al. (2008). Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. British Journal of Cancer, 99(10), 1695–1703.PubMedPubMedCentral
237.
Douchi, D., et al. (2015). Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/β-catenin signaling pathway. Cancer Letters, 365(1), 132–140.PubMed
238.
Ashrafizadeh, M., et al. (2022). Exosomes as promising nanostructures in diabetes mellitus: From insulin sensitivity to ameliorating diabetic complications. International Journal of Nanomedicine, 17, 1229–1253.PubMedPubMedCentral
239.
Paskeh, M. D. A., et al. (2022). Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology & Oncology, 15(1), 1–39.
240.
Li, J., et al. (2018). Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. Journal of Experimental & Clinical Cancer Research, 37(1), 177.
241.
Yu, Z., et al. (2017). Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation. Oncotarget, 8(38), 63461–63483.PubMedPubMedCentral
242.
Tang, P., et al. (2019). Serum derived exosomes from pancreatic cancer patients promoted metastasis: An iTRAQ-based proteomic analysis. Oncotargets and Therapy, 12, 9329–9339.PubMedPubMedCentral
243.
Ogawa, K., et al. (2020). Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Cancer Letters, 481, 63–75.PubMedPubMedCentral
244.
Kimoto, A., et al. (2023). Exosomes in ascites from patients with human pancreatic cancer enhance remote metastasis partially through endothelial-mesenchymal transition. Pancreatology, 23(4), 377–388.PubMed
245.
Zhou, X., et al. (2022). Pancreatic cancer cell-derived exosomes promote lymphangiogenesis by downregulating ABHD11-AS1 expression. Cancers (Basel), 14(19), 4612.PubMed
246.
Xu, Y., et al. (2020). Anticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cells. Aging (Albany NY), 12(19), 19660–19676.PubMed
247.
Wei, Q., et al. (2020). EphA2-enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer. Molecular Medicine Reports, 22(4), 2941–2947.PubMedPubMedCentral
248.
Zhang, Y. F., et al. (2019). Pancreatic cancer-derived exosomes promoted pancreatic stellate cells recruitment by pancreatic cancer. Journal of Cancer, 10(18), 4397–4407.PubMedPubMedCentral
249.
Nakayama, F., et al. (2022). Pancreatic cancer cell-derived exosomes induce epithelial-mesenchymal transition in human pancreatic cancer cells themselves partially via transforming growth factor β1. Medical Molecular Morphology, 55(3), 227–235.PubMedPubMedCentral
250.
Wang, X., et al. (2018). Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis. Cancer Research, 78(16), 4586–4598.PubMed
251.
Chen, K., et al. (2022). Hypoxic pancreatic cancer derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. International Journal of Biological Sciences, 18(3), 1220–1237.PubMedPubMedCentral
252.
Li, M., et al. (2022). Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1. Chinese Medical Journal, 135(19), 2326–2337.PubMedPubMedCentral
253.
Cao, W., et al. (2021). Hypoxic pancreatic stellate cell-derived exosomal mirnas promote proliferation and invasion of pancreatic cancer through the PTEN/AKT pathway. Aging (Albany NY), 13(5), 7120–7132.PubMed
254.
Li, Z., et al. (2018). Tumor-secreted exosomal miR-222 promotes tumor progression via regulating P27 expression and re-localization in pancreatic cancer. Cellular Physiology and Biochemistry, 51(2), 610–629.PubMed
255.
Sun, Z., et al. (2021). Exosomal linc-ROR mediates crosstalk between cancer cells and adipocytes to promote tumor growth in pancreatic cancer. Molecular Therapy--Nucleic Acids, 26, 253–268.PubMedPubMedCentral
256.
Wu, M., et al. (2020). Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis. Life Sciences, 255, 117857.PubMed
257.
Xie, Z., et al. (2022). Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Gut, 71(3), 568–579.PubMed
258.
He, Z., et al. (2022). Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Cancer Letters, 548, 215751.PubMed
259.
Costa-Silva, B., et al. (2015). Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biology, 17(6), 816–826.PubMedPubMedCentral
260.
Williams, C. B., Yeh, E. S., & Soloff, A. C. (2016). Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer, 2, 15025.PubMedPubMedCentral
261.
Ye, H., et al. (2018). Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death & Disease, 9(5), 453.
262.
Meng, F., et al. (2015). CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma. International Journal of Oncology, 46(3), 1109–1120.PubMed
263.
Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423–1437.PubMedPubMedCentral
264.
Chávez-Galán, L., et al. (2015). Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages. Frontiers in Immunology, 6, 263.PubMedPubMedCentral
265.
Tarique, A. A., et al. (2015). Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. American Journal of Respiratory Cell and Molecular Biology, 53(5), 676–688.PubMed
266.
Helm, O., et al. (2014). M1 and M2: there is no "good" and "bad"-How macrophages promote malignancy-associated features in tumorigenesis. Oncoimmunology, 3(7), e946818.PubMedPubMedCentral
267.
Stöger, J. L., et al. (2012). Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis, 225(2), 461–468.PubMed
268.
Genard, G., Lucas, S., & Michiels, C. (2017). reprogramming of tumor-associated macrophages with anticancer therapies: Radiotherapy versus chemo- and immunotherapies. Frontiers in Immunology, 8, 828.PubMedPubMedCentral
269.
Chang, Y. T., et al. (2020). Pancreatic cancer-derived small extracellular vesical Ezrin regulates macrophage polarization and promotes metastasis. American Journal of Cancer Research, 10(1), 12–37.PubMedPubMedCentral
270.
Nielsen, S. R., et al. (2016). Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology, 18(5), 549–560.PubMedPubMedCentral
271.
Liu, B., et al. (2016). Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. Acta Biochimica et Biophysica Sinica Shanghai, 48(12), 1067–1074.
272.
Thibault, B., et al. (2021). Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. EMBO Molecular Medicine, 13(7), e13502.PubMedPubMedCentral
273.
Griesmann, H., et al. (2017). Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Gut, 66(7), 1278–1285.PubMed
274.
Lin, L., et al. (2023). UTMD inhibits pancreatic cancer growth and metastasis by inducing macrophage polarization and vessel normalization. Biomedicine & Pharmacotherapy, 160, 114322.
275.
Novizio, N., et al. (2021). ANXA1 contained in EVs Regulates macrophage polarization in tumor microenvironment and promotes pancreatic cancer progression and metastasis. International Journal of Molecular Sciences, 22(20), 11018.PubMedPubMedCentral
276.
Song, Y., et al. (2023). Circ_0018909 knockdown inhibits the development of pancreatic cancer via the miR-545-3p/FASN axis and reduces macrophage polarization to M2. Journal of Biochemical and Molecular Toxicology, 37(4), e23293.PubMed
277.
Kurahara, H., et al. (2013). M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas, 42(1), 155–159.PubMed
278.
Ma, X., et al. (2016). The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR/AKT/CREB pathway. Oncology Reports, 35(1), 189–196.PubMed
279.
Geng, Y., et al. (2021). A notch-dependent inflammatory feedback circuit between macrophages and cancer cells regulates pancreatic cancer metastasis. Cancer Research, 81(1), 64–76.PubMed
280.
Wu, J., et al. (2022). TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. International Immunopharmacology, 102, 108429.PubMed
281.
Chen, Q., et al. (2019). Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. British Journal of Cancer, 121(9), 786–795.PubMedPubMedCentral
282.
Gu, H., et al. (2022). NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma. Translational Lung Cancer Research, 11(5), 858–868.PubMedPubMedCentral
283.
Menen, R. S., et al. (2012). Tumor-educated macrophages promote tumor growth and peritoneal metastasis in an orthotopic nude mouse model of human pancreatic cancer. In Vivo, 26(4), 565–569.PubMed
284.
Penny, H. L., et al. (2016). Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology, 5(8), e1191731.PubMedPubMedCentral
285.
Liu, C. Y., et al. (2013). M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Laboratory Investigation, 93(7), 844–854.PubMed
286.
287.
Niu, N., et al. (2023). Tumor Cell-Intrinsic SETD2 Deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis. Advanced Science(Weinh), 10(2), e2202937.
288.
Papayannopoulos, V. (2018). Neutrophil extracellular traps in immunity and disease. Nature Reviews. Immunology, 18(2), 134–147.PubMed
289.
Cedervall, J., & Olsson, A. K. (2016). Immunity gone astray - NETs in cancer. Trends Cancer, 2(11), 633–634.PubMed
290.
Deng, J., et al. (2021). DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. JCI Insight, 6(17), e146133.PubMedPubMedCentral
291.
Kajioka, H., et al. (2021). Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Cancer Letters, 497, 1–13.PubMed
292.
Miller-Ocuin, J. L., et al. (2019). DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth. Oncoimmunology, 8(9), e1605822.PubMedPubMedCentral
293.
Takesue, S., et al. (2020). Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer-associated fibroblasts. International Journal of Oncology, 56(2), 596–605.PubMed
294.
Bellomo, G., et al. (2022). Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut, 71(11), 2284–2299.PubMed
295.
Lianyuan, T., et al. (2020). Tumor associated neutrophils promote the metastasis of pancreatic ductal adenocarcinoma. Cancer Biology & Therapy, 21(10), 937–945.
296.
Li, Y. X., et al. (2022). ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pancreatic cancer. Cancer Letters, 544, 215802.PubMed
297.
Cai, W., et al. (2021). PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Cancer Letters, 515, 86–95.PubMed
298.
Zaghdoudi, S., et al. (2020). FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. EMBO Molecular Medicine, 12(11), e12010.PubMedPubMedCentral
299.
Chu, X., Yang, Y., & Tian, X. (2022). Crosstalk between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in the Tumor Microenvironment Mediated by Exosomal MicroRNAs. International Journal of Molecular Sciences, 23(17), 9512.PubMedPubMedCentral
300.
Stylianou, A., Gkretsi, V., & Stylianopoulos, T. (2018). Transforming growth factor-β modulates pancreatic cancer associated fibroblasts cell shape, stiffness and invasion. Biochimica et Biophysica Acta - General Subjects, 1862(7), 1537–1546.PubMed
301.
Goicoechea, S. M., et al. (2014). Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Oncogene, 33(10), 1265–1273.PubMed
302.
Shan, T., et al. (2017). Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism. Oncology Reports, 37(4), 1971–1979.PubMedPubMedCentral
303.
Wang, Q., et al. (2017). Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. American Journal of Cancer Research, 7(1), 125–133.PubMedPubMedCentral
304.
Chen, X., et al. (2021). CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway. Acta Biochimica et Biophysica Sinica Shanghai, 53(5), 612–619.
305.
Liu, J., et al. (2020). Cell metabolomics reveals berberine-inhibited pancreatic cancer cell viability and metastasis by regulating citrate metabolism. Journal of Proteome Research, 19(9), 3825–3836.PubMed
306.
Tian, W., et al. (2022). Berberine suppresses lung metastasis of cancer via inhibiting endothelial transforming growth factor beta receptor 1. Frontiers in Pharmacology, 13, 917827.PubMedPubMedCentral
307.
Kim, S. O., & Kim, M. R. (2013). (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC-1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. International Journal of Oncology, 42(1), 349–358.PubMed
308.
Arya, G., Das, M., & Sahoo, S. K. (2018). Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer. Biomedicine & Pharmacotherapy, 102, 555–566.
309.
Hoca, M., et al. (2020). The effect of resveratrol and quercetin on epithelial-mesenchymal transition in pancreatic cancer stem cell. Nutrition and Cancer, 72(7), 1231–1242.PubMed
310.
Li, W., et al. (2013). Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Current Medicinal Chemistry, 20(33), 4185–4194.PubMedPubMedCentral
311.
Yu, D., et al. (2017). Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells. Oncotargets and Therapy, 10, 4719–4729.PubMedPubMedCentral
312.
Guo, Y., et al. (2021). Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Cell Biology and Toxicology, 37(3), 479–496.PubMed
313.
Srivastava, R. K., et al. (2011). Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Frontiers in Bioscience (Elite Edition), 3(2), 515–528.PubMed
314.
Lee, J., et al. (2016). Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro. Oncology Reports, 35(4), 2473–2479.PubMed
315.
Wang, C., et al. (2021). Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein & Cell, 12(2), 128–144.
316.
Yu, X., et al. (2020). Propofol affects the growth and metastasis of pancreatic cancer via ADAM8. Pharmacological Reports, 72(2), 418–426.PubMed
317.
Polireddy, K., et al. (2017). High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Scientific Reports, 7(1), 17188.PubMedPubMedCentral
318.
Yamada, S., et al. (2020). Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. The British Journal of Surgery, 107(13), 1811–1817.PubMed
319.
Takahara, N., et al. (2021). A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Investigational New Drugs, 39(1), 175–181.PubMed
320.
Nishiyama, Y., et al. (2005). Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Annals of Nuclear Medicine, 19(6), 491–497.PubMed
321.
Ishikawa, T., et al. (2007). Angiotensin-II administration is useful for the detection of liver metastasis from pancreatic cancer during pharmacoangiographic computed tomography. World Journal of Gastroenterology, 13(22), 3080–3083.PubMedPubMedCentral
322.
Hayashibe, A., et al. (2007). Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer. Annals of Surgical Oncology, 14(1), 190–194.PubMed
323.
Wobser, M., et al. (2006). Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunology, Immunotherapy, 55(10), 1294–1298.PubMed
Metadata
Title
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance
Authors
Zhenli Guo
Milad Ashrafizadeh
Wei Zhang
Rongjun Zou
Gautam Sethi
Xianbin Zhang
Publication date
15-07-2023
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2024
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-023-10125-y

Other articles of this Issue 1/2024

Cancer and Metastasis Reviews 1/2024 Go to the issue

REVIEW

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Review

Resveratrol as sensitizer in colorectal cancer plasticity

REVIEW

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

REVIEW

Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics

REVIEW

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

Review

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits